Canadian Clinical Experience on Switching From Standard Half‐life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half‐life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Ca
This is a plain language summary on switching from the medicine octocog alfa to a new medicine damoctocog alfa pegol (BAY 94-9027, Jivi) for the treatment of haemophilia A in Canada.
Authors
- Emma Iserman (ORCID: https://orcid.org/0000-0001-7539-6490)
- Andrea N. Edginton (ORCID: https://orcid.org/0000-0002-9014-1653)
- Kay Decker (ORCID: https://orcid.org/0000-0002-6847-3192)
- Alfonso Iorio (ORCID: https://orcid.org/0000-0002-3331-8766)
- Davide Matino (ORCID: https://orcid.org/0000-0002-9902-4074)
- Elisabetta Trinari (ORCID: https://orcid.org/0000-0001-5859-652X)
- Arun Keepanasseril (ORCID: https://orcid.org/0000-0003-0733-9616)
- Olayide Oladoyinbo
Institutions
- University of Waterloo (CA)
- Impact (CA)
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1111/hae.70145
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00